Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the…
Consensus price target: $120.00 (+17042.86% upside from $0.70)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Camaisa Allan director | Dec 12, 2025 | Sale | 850 | $1.24K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-19.91M |
| 2024 | $0 | — | $-22.14M |
| 2023 | $0 | -100% | $-29.22M |
Stock data for CLDI: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics